Cite
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
MLA
Emily K. Kleczko, et al. “Durable Responses to Alectinib in Murine Models of EML4-ALK Lung Cancer Requires Adaptive Immunity.” Npj Precision Oncology, vol. 7, no. 1, Feb. 2023, pp. 1–11. EBSCOhost, https://doi.org/10.1038/s41698-023-00355-2.
APA
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, Natalia J. Gurule, Andre Navarro, Anh T. Le, Amber M. Johnson, Jeff Kwak, Diana I. Polhac, Eric T. Clambey, Mary Weiser-Evans, Daniel T. Merrick, Michael C. Yang, Tejas Patil, Erin L. Schenk, Lynn E. Heasley, & Raphael A. Nemenoff. (2023). Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. Npj Precision Oncology, 7(1), 1–11. https://doi.org/10.1038/s41698-023-00355-2
Chicago
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, Natalia J. Gurule, Andre Navarro, Anh T. Le, Amber M. Johnson, et al. 2023. “Durable Responses to Alectinib in Murine Models of EML4-ALK Lung Cancer Requires Adaptive Immunity.” Npj Precision Oncology 7 (1): 1–11. doi:10.1038/s41698-023-00355-2.